[
  {
    "ts": "2025-12-25T02:05:00+00:00",
    "headline": "Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies",
    "summary": "Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie",
    "url": "https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "275dceb5-bed9-33b6-b0c8-8ed3f7c655a6",
      "content": {
        "id": "275dceb5-bed9-33b6-b0c8-8ed3f7c655a6",
        "contentType": "STORY",
        "title": "Caliway's Fat Reduction Drug Candidate CBL-514 Completes U.S. FDA IND Submission for Phase 2 Clinical Study in Weight Management, Expanding Development Combined with GLP-1RA-Based Weight-Loss Therapies",
        "description": "",
        "summary": "Caliway Biopharmaceuticals (TWSE: 6919) today announced that it has completed the submission of an Investigational New Drug (IND) application to the U.S. FDA for a Phase 2 clinical study of its world's first large-area localized fat reduction drug candidate, CBL-514, for the weight management indication. This submission accelerates the clinical development of CBL-514 in combination with GLP-1R agonist (GLP-1RA) therapies and expands the Company's R&D footprint in the global weight management fie",
        "pubDate": "2025-12-25T02:05:00Z",
        "displayTime": "2025-12-25T02:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39",
          "originalWidth": 400,
          "originalHeight": 118,
          "caption": "Caliway Biopharmaceuticals (PRNewsfoto/Caliway Biopharmaceuticals)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/a5AnGJR.rdINSCnWGbgkAg--~B/aD0xMTg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39.cf.webp",
              "width": 400,
              "height": 118,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.f0eEj_4woeYc9Ub4_xv5w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1a518489f118ff257bae06654e61bd39.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/caliways-fat-reduction-drug-candidate-020500815.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-25T05:47:19+00:00",
    "headline": "Asian shares are mixed after US stocks drift to more records",
    "summary": "Asian shares were mixed Thursday in thin holiday trading, with most markets in the region and elsewhere closed for Christmas.  U.S. markets will reopen for a full day of trading on Friday, though volumes will likely remain light this week with most investors having closed out their positions for the year.",
    "url": "https://finance.yahoo.com/news/asian-shares-mixed-us-stocks-054719908.html",
    "source": "Associated Press Finance",
    "provider": "yfinance",
    "raw": {
      "id": "1889aaa5-9887-3a1a-b977-0510660d5a15",
      "content": {
        "id": "1889aaa5-9887-3a1a-b977-0510660d5a15",
        "contentType": "STORY",
        "title": "Asian shares are mixed after US stocks drift to more records",
        "description": "",
        "summary": "Asian shares were mixed Thursday in thin holiday trading, with most markets in the region and elsewhere closed for Christmas.  U.S. markets will reopen for a full day of trading on Friday, though volumes will likely remain light this week with most investors having closed out their positions for the year.",
        "pubDate": "2025-12-25T05:47:19Z",
        "displayTime": "2025-12-25T05:47:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ap_finance_articles_694/9fc982f53f663d1ebe386c046f0003a6",
          "originalWidth": 5165,
          "originalHeight": 3443,
          "caption": "Derek Orth works on the floor at the New York Stock Exchange in New York, Wednesday, Dec. 10, 2025. (AP Photo/Seth Wenig)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hXoB7nANzpb3efqOH_gzwg--~B/aD0zNDQzO3c9NTE2NTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/ap_finance_articles_694/9fc982f53f663d1ebe386c046f0003a6.cf.webp",
              "width": 5165,
              "height": 3443,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3jygL.AsvnVl73AZvEArZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ap_finance_articles_694/9fc982f53f663d1ebe386c046f0003a6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Associated Press Finance",
          "url": "http://www.ap.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/asian-shares-mixed-us-stocks-054719908.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/asian-shares-mixed-us-stocks-054719908.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^N225"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "EUR=X"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "DVAX"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^IXIC"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "SNY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-25T11:40:28+00:00",
    "headline": "Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says",
    "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market before cheaper generic version enter stores in March, Rishika Sadam of Reuters reports. Novo’s strategy focuses on price cuts and accelerated launches while Lilly’s products benefitted from entering the market early. Both companies have outreached to doctors, advertised heavily, provided incentives to patients, and entered distribution deals with local drugmakers, doctors, analysis, and others i",
    "url": "https://finance.yahoo.com/news/novo-lilly-race-cement-lead-114028860.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "59c8c41f-e1b0-34d1-a798-938ede3a1661",
      "content": {
        "id": "59c8c41f-e1b0-34d1-a798-938ede3a1661",
        "contentType": "STORY",
        "title": "Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says",
        "description": "",
        "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market before cheaper generic version enter stores in March, Rishika Sadam of Reuters reports. Novo’s strategy focuses on price cuts and accelerated launches while Lilly’s products benefitted from entering the market early. Both companies have outreached to doctors, advertised heavily, provided incentives to patients, and entered distribution deals with local drugmakers, doctors, analysis, and others i",
        "pubDate": "2025-12-25T11:40:28Z",
        "displayTime": "2025-12-25T11:40:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/novo-lilly-race-to-cement-lead-in-indias-obesity-drug-market-reuters-says-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ACqvkrEAR9bKVC147W0pXQ--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.1s0uqhS6UrZL9IPafc8Vw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/ce0712556f8b4e54fa2af52107a5b0b6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-lilly-race-cement-lead-114028860.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-lilly-race-cement-lead-114028860.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-12-25T11:08:27+00:00",
    "headline": "Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program",
    "summary": "In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support Viking’s own oral obesity drug program. This external validation of Viking’s lead candidate VK2735 has sharpened investor focus on the company’s potential role in the rapidly evolving obesity treatment market. We’ll now examine how this strengthened confidence in VK2735’s commercial prospects...",
    "url": "https://finance.yahoo.com/news/viking-therapeutics-vktx-8-9-110827748.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3bf2f293-613e-3a4e-bdfb-9bb7de6d6abf",
      "content": {
        "id": "3bf2f293-613e-3a4e-bdfb-9bb7de6d6abf",
        "contentType": "STORY",
        "title": "Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program",
        "description": "",
        "summary": "In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support Viking’s own oral obesity drug program. This external validation of Viking’s lead candidate VK2735 has sharpened investor focus on the company’s potential role in the rapidly evolving obesity treatment market. We’ll now examine how this strengthened confidence in VK2735’s commercial prospects...",
        "pubDate": "2025-12-25T11:08:27Z",
        "displayTime": "2025-12-25T11:08:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-vktx-8-9-110827748.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/viking-therapeutics-vktx-8-9-110827748.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]